Last10K.com

Kiromic Biopharma, Inc. (KRBP) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Kiromic Biopharma, Inc.

HISTORY TOOLS
CIK: 1792581 Ticker: KRBP

​

Kiromic BioPharma Provides Business Update and

Reports Third Quarter 2021 Financial Results

​

Quarter Updates Include Company’s Progress in the Following Areas:

​

Expansion of DIAMOND® AI Platform to More than 1.5 Billion Data Points

​

Completion of InSilico Solutions, LLC Acquisition

​

Closing of Public Offering

​

Addition of Key Personnel Across Bioinformatics, Clinical Translational, Manufacturing, and Operations

 

HOUSTON, March 11, 2022 – Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”)

, a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today reported business updates and financial results for its third quarter ending September 30, 2021.

 

“We believe that we made meaningful progress during the third quarter of 2021 with our corporate developments and with our chemical manufacturing and control manufacturing processes. We believe these developments will allow us to effectively address the FDA clinical hold comments, and will ensure that we are well positioned to advance our oncology cell therapy trial candidates. We were also able to recently complete an internal review associated with certain complaints that the Company received through its complaint hotline. The internal review was conducted by a Special Committee of our Board of Directors.  The Company was precluded from filing its Form 10-Q in November 2021 pending completion of the internal review,” stated Pietro Bersani, interim Chief Executive Officer of Kiromic BioPharma.

Mr. Bersani continued: “As a result of the internal review, we also appointed two new board members, Frank Tirelli and Karen Reeves, and appointed Michael Nagel as the chairperson of our board of directors. We also established a disclosure committee, which is charged with preparing and overseeing all corporate disclosures made by the Company in response to the ineffectiveness of our disclosure controls and procedures  outlined in the Form 8-K filed on February 2, 2022. Accordingly, we anticipate providing more updates and increasing the frequency of our shareholder communications as we report on our progress and upcoming milestones.”

Recent Business Highlights:

​

●Surpassed 1.5 billion Data Points Powering Kiromic’s DIAMOND®AI Platform for Drug Discovery and Development: The Company added approximately 300 million data points in 2021, representing a 25% increase from 2020. Kiromic’s growing machine learning platform

1

​

The following information was filed by Kiromic Biopharma, Inc. (KRBP) on Friday, March 11, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Kiromic Biopharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kiromic Biopharma, Inc..

Continue

Assess how Kiromic Biopharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kiromic Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Mgmt Change
M & A
Other
Filter Subcategory:
All
Expense
Earnings
Product
Cash Flow
Other
Inside Kiromic Biopharma, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Stockholders' Equity
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details)
Accrued Expenses And Other Current Liabilities (Tables)
Acquisitions
Acquisitions (Details)
Acquisitions (Tables)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Facility Lease Agreements (Details)
Commitments And Contingencies - Legal Proceedings (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Deferred Tax Assets And Liabilities (Details)
Income Taxes - Net Operating Loss Carryforward (Details)
Income Taxes - Tax Rate Reconciliation (Details)
Loan Payable
Loan Payable (Details)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Tables)
Net Loss Per Share Of Common Stock - Computation Of Basic And Diluted Earnings Per Share (Details)
Net Loss Per Share Of Common Stock - Dilutive Securities Excluded From The Computations Of Earnings Per Share (Details)
Note Payable
Note Payable (Details)
Organization
Organization (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Related Party Transactions
Related Party Transactions (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 2017 And 2021 Stock Incentive Plan-Restricted Stock Units (Details)
Stock-Based Compensation - Stock Option Modifications (Details)
Stock-Based Compensation - Summarizes Stock Options Outstanding (Details)
Stock-Based Compensation - Weighted-Average Assumptions (Details)
Stockholders Equity
Stockholders Equity (Tables)
Stockholders Equity - Common Stock (Details)
Stockholders Equity - Estimate The Fair Value Of The Warrants (Details)
Stockholders Equity - Information (Details)
Stockholders Equity - Initial Value Of Issuances Allocated To Series B Preferred Stock And The Series B Preferred Stock (Details)
Stockholders Equity - Preferred Stock (Details)
Stockholders Equity - Representative's Warrants (Details)
Stockholders Equity - Warrants Underlying Series B Preferred Stock (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Fair Value Measurements (Details)
Summary Of Significant Accounting Policies - Nonvested Stock Options (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Ticker: KRBP
CIK: 1792581
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-005217
Submitted to the SEC: Fri Apr 08 2022 4:15:43 PM EST
Accepted by the SEC: Fri Apr 08 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/krbp/0001558370-22-005217.htm